Gastrointestinal Cancer | Topics

Pembrolizumab Plus Chemotherapy Combination Improves Survival in Esophageal Squamous Cell Carcinoma
September 21, 2021

Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.

Patients With Frontline Gastric/GEJ Cancers Benefit When Nivolumab Is Added to Chemotherapy
September 19, 2021

Data presented at 2021 ESMO show that nivolumab plus chemotherapy improves survival outcomes in certain patients with frontline gastrointestinal cancers, but not nivolumab plus ipilimumab.

Patients With Esophageal Squamous Cell Carcinoma Treated With Frontline Toripalimab Plus Chemo Derive Survival Benefit
September 18, 2021

Results from the phase 3 JUPITER06 trial demonstrated positive outcomes with toripalimab plus platinum-based chemotherapy in patients with treatment-naïve advanced or metastatic esophageal squamous cell carcinoma.